Attitudes Towards Buprenorphine and Methadone

Attitudes of Patients With Opioid-Substitution and Their Therapists Towards and Buprenorphine and Methadone

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00911846

Acronym

Att-1

Enrollment

180

Registered

2009-06-02

Start date

2009-05-31

Completion date

2010-06-30

Last updated

2009-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addictive, Opioids

Keywords

opioid dependence substitution buprenorphine methadone, substitution

Brief summary

Main intention of this study is to find out whether there is a difference between the attitudes towards opioid- substitution of opioid dependent patients under substitution with methadone, buprenorphine or without substitution and their therapists

Detailed description

Attitudes of patients and therapists can influence therapy success in both directions. Not much is known about patients' and their therapists' attitudes towards substitution medication. Our hypothesis is that the attitude towards buprenorphine is more positive than towards methadone even in patients taking methadone. Better knowledge about the influence of attitudes on treatment success could facilitate to adapt therapy to the patients' needs.

Interventions

OTHERinterview

interview using questionnaires

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Age between 18 and 65 years * Opioid-dependent with substitution with buprenorphine, * methadone or without substitution * Sufficient knowledge of German language

Exclusion criteria

* Inability to give informed consent

Design outcomes

Primary

Measure	Time frame
Attitude toward buprenorphine compared over the four groups	one time of measurement

Secondary

Measure	Time frame
Treatment success; Treatment conditions; Consumption of substances	one point of measurement

Countries

Switzerland

Contacts

Primary ContactRia Leisinger, MD

ria.leisinger@puk.zh.ch0041 44 384 27 87

Backup ContactRudolf Stohler, MD

rudolf.stohler@puk.zh.ch0041 44 205 58 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026